Summary Polycomb Group (PcG) proteins play an essential role in the epigenetic maintenance of repressive chromatin states. The gene silencing activity of the Polycomb Repressive Complex 2 (PRC2) depends on its ability to tri-methylate lysine 27 of histone H3 (H3K27) via the catalytic SET domain of the EZH2 subunit, and at least two other subunits of the complex: Suz12 and Eed. We show that the C-terminal domain of Eed specifically binds to histone tails carrying tri-methyl lysine residues associated with repressive chromatin marks and that this leads to the allosteric activation of the methyltransferase activity of PRC2. Mutations in Eed that prevent it from recognising repressive trimethyl-lysine marks abolish activation of PRC2 in vitro and, in Drosophila, reduces global methylation and disrupts development. These findings suggest a model for the propagation of the H3K27me3 mark that accounts for the maintenance of repressive chromatin domains and for the transmission of a histone modification from mother to daughter cells.

SUMMARY Mononucleosomes, the basic building blocks of chromatin, contain two copies of each core histone. The associated posttranslational modifications regulate essential chromatin-dependent processes, yet whether each histone copy is identically modified in vivo is unclear. We demonstrate that nucleosomes in embryonic stem cells, fibroblasts, and cancer cells exist in both symmetrically and asymmetrically modified populations for histone H3 lysine 27 di/trimethylation (H3K27me2/3) and H4K20me1. To explore implications of nucleosomal asymmetry, we analyzed co-occurrence of histone marks and obtained direct physical evidence for bivalent nucleosomes carrying H3K4me3 or H3K36me3 along with H3K27me3, albeit on opposite H3 tails. Bivalency at target genes was resolved upon differentiation of ES cells. Polycomb Repressive Complex 2-mediated methylation of H3K27 was inhibited when nucleosomes contain symmetrically, but not asymmetrically, placed H3K4me3 or H3K36me3. These findings uncover a potential mechanism for the incorporation of bivalent features into nucleosomes and demonstrate how asymmetry might set the stage to diversify functional nucleosome states.

The NSD (nuclear receptor SET domain-containing) family of histone lysine methyltransferases is a critical participant in chromatin integrity as evidenced by the number of human diseases associated with the aberrant expression of its family members. Yet, the specific targets of these enzymes are not clear, with marked discrepancies being reported in the literature. We demonstrate that NSD2 can exhibit disparate target preferences based on the nature of the substrate provided. The NSD2 complex purified from human cells and recombinant NSD2 both exhibit specific targeting of histone H3 lysine 36 (H3K36) when provided with nucleosome substrates, but histone H4 lysine 44 is the primary target in the case of octamer substrates, irrespective of the histones being native or recombinant. This disparity is negated when NSD2 is presented with octamer targets in conjunction with short single- or double-stranded DNA. Although the octamers cannot form nucleosomes, the target is nonetheless nucleosome-specific as is the product, dimethylated H3K36. This study clarifies in part the previous discrepancies reported with respect to NSD targets. We propose that DNA acts as an allosteric effector of NSD2 such that H3K36 becomes the preferred target.

The carboxy-terminal domain (CTD) of RNA polymerase II (RNAPII) in mammals undergoes extensive posttranslational modification, which is essential for transcriptional initiation and elongation. Here, we show that the CTD of RNAPII is methylated at a single arginine (R1810) by the coactivator-associated arginine methyltransferase 1 (CARM1). Although methylation at R1810 is present on the hyperphosphorylated form of RNAPII in vivo, Ser2 or Ser5 phosphorylation inhibits CARM1 activity toward this site in vitro, suggesting that methylation occurs before transcription initiation. Mutation of R1810 results in the misexpression of a variety of small nuclear RNAs and small nucleolar RNAs, an effect that is also observed in Carm1−/− mouse embryo fibroblasts. These results demonstrate that CTD methylation facilitates the expression of select RNAs, perhaps serving to discriminate the RNAPII-associated machinery recruited to distinct gene types.

Over the past decade, foldamers have progressively emerged as useful architectures to mimic secondary structures of proteins. Peptidic foldamers, consisting of various amino acid based backbones, have been the most studied from a therapeutic perspective, while polyaromatic foldamers have barely evolved from their nascency and remain perplexing for medicinal chemists due to their poor drug-like nature. Despite these limitations, this compound class may still offer opportunities to study challenging targets or provide chemical biology tools. The potential of foldamer drug candidates reaching the clinic is still a stretch. Nevertheless, advances in the field have demonstrated their potential for the discovery of next generation therapeutics. In this perspective, the current knowledge of foldamers is reviewed in a drug discovery context. Recent advances in the early phases of drug discovery including hit finding, target validation, and optimization and molecular modeling are discussed. In addition, challenges and focus areas are debated and gaps highlighted.

For a long time, C2-symmetric ligands have dominated in asymmetric catalysis. More recently, nonsymmetrical modular P,N-ligands have been introduced. These ligands have been applied successfully in various metal-catalyzed reactions and, in many cases, have outperformed P,P-or N,N-ligands.M ost asymmetric catalysts that have been developed so far are metal complexes with chiral organic ligands. The chiral ligand modifies the reactivity and selectivity of the metal center in such a way that one of two possible enantiomeric products is formed preferentially. Based on this concept, many metal complexes have been found that catalyze various reactions with impressive enantioselectivity. Despite impressive progress in this field, the design of suitable chiral ligands for a particular application remains a formidable task. The complexity of most catalytic processes precludes a purely rational approach based on mechanistic and structural criteria. Therefore, most new chiral catalysts are still found empirically, with chance, intuition, and systematic screening all playing important roles. Nevertheless, for certain reactions such as Rh-catalyzed hydrogenation (1, 2) or Pd-catalyzed allylic substitution (3, 4), the mechanism is known, allowing at least a semirational approach to catalyst development. Moreover, useful general concepts have been developed during the last three decades that greatly facilitate the development of new chiral ligands, even in the absence of mechanistic information. Some of these concepts are described in the following sections, mainly from the perspective of our own research.

No abstract

Receptor-dependent productive uptake of GLP1-conjugated antisense oligonucleotides occurs selectively in pancreatic β-cells.